|
Valoración de DCF de Nurix Therapeutics, Inc. (NRIX)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Nurix Therapeutics, Inc. (NRIX) Bundle
¡Simplifique la valoración de Nurix Therapeutics, Inc. (NRIX) con esta calculadora DCF personalizable! Con Real Nurix Therapeutics, Inc. (NRIX) financieras y entradas de pronóstico ajustables, puede probar escenarios y descubrir el valor razonable de Nurix Therapeutics, Inc. (NRIX) en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.1 | 17.8 | 29.8 | 38.6 | 77.0 | 106.5 | 147.3 | 203.8 | 282.0 | 390.1 |
| Revenue Growth, % | 0 | -42.73 | 66.95 | 29.84 | 99.31 | 38.34 | 38.34 | 38.34 | 38.34 | 38.34 |
| EBITDA | -19.9 | -62.8 | -111.8 | -173.1 | -141.4 | -98.8 | -136.7 | -189.1 | -261.6 | -361.9 |
| EBITDA, % | -63.9 | -352.43 | -375.81 | -448.03 | -183.68 | -92.78 | -92.78 | -92.78 | -92.78 | -92.78 |
| Depreciation | 2.4 | 2.2 | 6.1 | 10.8 | 13.7 | 18.3 | 25.3 | 35.0 | 48.5 | 67.1 |
| Depreciation, % | 7.57 | 12.23 | 20.44 | 27.98 | 17.74 | 17.19 | 17.19 | 17.19 | 17.19 | 17.19 |
| EBIT | -22.2 | -65.0 | -117.9 | -183.9 | -155.1 | -100.4 | -138.9 | -192.2 | -265.9 | -367.8 |
| EBIT, % | -71.46 | -364.66 | -396.26 | -476.01 | -201.41 | -94.29 | -94.29 | -94.29 | -94.29 | -94.29 |
| Total Cash | 37.7 | 281.1 | 295.7 | 309.1 | 287.9 | 106.5 | 147.3 | 203.8 | 282.0 | 390.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 11.3 | 6.2 | .0 | .0 | 18.0 | 24.9 | 34.5 | 47.7 | 65.9 |
| Account Receivables, % | 0 | 63.67 | 20.85 | 0 | 0 | 16.9 | 16.9 | 16.9 | 16.9 | 16.9 |
| Inventories | .0 | .0 | .0 | -1.1 | .0 | -.6 | -.8 | -1.2 | -1.6 | -2.2 |
| Inventories, % | 0 | 0 | 0.000003361345 | -2.85 | 0 | -0.56955 | -0.56955 | -0.56955 | -0.56955 | -0.56955 |
| Accounts Payable | 1.6 | 3.4 | 6.7 | 5.1 | 6.4 | 14.5 | 20.1 | 27.7 | 38.4 | 53.1 |
| Accounts Payable, % | 5.14 | 19.15 | 22.35 | 13.11 | 8.31 | 13.61 | 13.61 | 13.61 | 13.61 | 13.61 |
| Capital Expenditure | -1.7 | -4.6 | -5.7 | -12.2 | -8.4 | -19.7 | -27.3 | -37.7 | -52.2 | -72.2 |
| Capital Expenditure, % | -5.31 | -25.55 | -19.03 | -31.7 | -10.91 | -18.5 | -18.5 | -18.5 | -18.5 | -18.5 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -22.5 | -44.1 | -118.0 | -169.3 | -155.1 | -92.4 | -127.8 | -176.8 | -244.5 | -338.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -20.2 | -56.0 | -109.2 | -165.0 | -149.6 | -103.1 | -130.8 | -181.0 | -250.4 | -346.4 |
| WACC, % | 14.54 | 14.5 | 14.54 | 14.53 | 14.54 | 14.53 | 14.53 | 14.53 | 14.53 | 14.53 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -631.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -353 | |||||||||
| Terminal Value | -2,820 | |||||||||
| Present Terminal Value | -1,431 | |||||||||
| Enterprise Value | -2,063 | |||||||||
| Net Debt | -24 | |||||||||
| Equity Value | -2,039 | |||||||||
| Diluted Shares Outstanding, MM | 54 | |||||||||
| Equity Value Per Share | -37.52 |
What You Will Get
- Comprehensive NRIX Financials: Access to both historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Nurix Therapeutics' future performance.
- User-Friendly Interface: Designed for experts while remaining approachable for newcomers.
Key Features
- Comprehensive Financial Data: Access precise pre-loaded historical performance and future forecasts for Nurix Therapeutics, Inc. (NRIX).
- Adjustable Projection Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Instant updates to DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Visualization Tools: User-friendly charts and summaries to illustrate your valuation findings.
- Designed for All Levels: An intuitive layout suitable for investors, CFOs, and consultants alike.
How It Works
- Download the Template: Gain immediate access to the Excel-based NRIX DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically recalculates Nurix Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation changes.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose This Calculator for Nurix Therapeutics, Inc. (NRIX)?
- Accurate Data: Utilize real Nurix Therapeutics financials for trustworthy valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations streamline the process, saving you from starting from scratch.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Featuring an intuitive design and clear step-by-step guidance for users of all experience levels.
Who Should Use This Product?
- Biotech Students: Understand drug development processes and apply them using real-world examples.
- Researchers: Integrate advanced therapeutic models into studies or publications.
- Investors: Evaluate your own hypotheses and assess valuation scenarios for Nurix Therapeutics, Inc. (NRIX).
- Analysts: Enhance your analysis with a comprehensive, customizable financial model.
- Pharmaceutical Entrepreneurs: Discover how major biotech firms like Nurix Therapeutics are evaluated.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Nurix Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Nurix Therapeutics, Inc. (NRIX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.